Research programme: anti-HIV chimeric antigen receptor T cell therapies - Legend Biotech USA
Latest Information Update: 28 Sep 2025
At a glance
- Originator Legend Biotech USA
- Developer Beth Israel Deaconess Medical Center; Legend Biotech USA
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 28 Sep 2025 No recent reports of development identified for preclinical development in HIV-infections in USA (Parenteral)
- 26 Aug 2021 Preclinical trials in HIV infections in USA (Parenteral) (Legend Biotech pipeline, August 2021)